GOLDMAN SACHS ON NEULAND LABS • Reiterate Buy, target price 12,975 from Rs 11,400 • FDA approval for Cobenfy is a key event • FY26 Xanomile estimates to be up 55-60% • CDMO business multiple raised to 40x from 37x GOLDMAN SACHS ON NEULAND LABS • Reiterate Buy, target price 12,975 from Rs 11,400 • FDA approval for Cobenfy is a key event • FY26 Xanomile estimates to be up 55-60% • CDMO business multiple raised to 40x from 37x
GOLDMAN SACHS ON NEULAND LABS
• Reiterate Buy, target price 12,975 from Rs 11,400
• FDA approval for Cobenfy is a key event
• FY26 Xanomile estimates to be up 55-60%
• CDMO business multiple raised to 40x from 37x GOLDMAN SACHS ON NEULAND LABS
• Reiterate Buy, target price 12,975 from Rs 11,400
• FDA approval for Cobenfy is a key event
• FY26 Xanomile estimates to be up 55-60%
• CDMO business multiple raised to 40x from 37x
Please follow and like us:
Comments are closed.